부산대학교 도서관

The patient was found to be I PIK3CA i -mutated on droplet digital polymerase chain reaction (ddPCR) testing, which is plausibly one of the causative links to the HER2-directed therapy resistance. Platinum-based anthracyclines and taxane-based chemotherapy regimens have been studied in aSDC with variable responses.[3] Majority of SDC cases express AR (66.7%-96.4%) and/or HER2 (15%-44%), thus making HER2-directed therapy a viable treatment option. In their work on breast cancer cell lines, He et al[26] have demonstrated the critical role of AR cross-talk with HER2 leading to HER2-directed therapy resistance. Salivary duct carcinoma (SDC) is an aggressive adenocarcinoma of the salivary gland with high rates of metastasis and mortality with 5-year survival rates between 23%-42% versus other more common, salivary gland carcinomas such as adenoid cystic carcinoma (89%) and mucoepidermoid carcinoma (79.3%).[1] Even for SDCs managed with curative intent with surgery with or without adjuvant radiation, there is a high rate of locoregional recurrence (48%) or distant metastasis (48%).[2] The sensitivity of advanced SDC (aSDC) to chemotherapy has been reported in the past with variable responses.[3],[4] However, in recent years, large numbers of somatic mutations have been identified where targeted therapies have shown great success. [Extracted from the article]